Imagen de Portada

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthias Kelm, Sven Flemming
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
por: Nathan Grellier, et al.
Publicado: (2025)

The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease
por: Sebastiaan ten Bokkel Huinink, et al.
Publicado: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
por: Tamar Schildkraut, et al.
Publicado: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
por: Dingsheng Liu, et al.
Publicado: (2025)

Early ileal resection in Crohn's disease is not associated with severe long‐term outcomes: The ERIC study
por: Nathan Grellier, et al.
Publicado: (2024)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
por: Kuan‐Ju Lin, et al.
Publicado: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
por: Jiacheng Li
Publicado: (2026)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
por: José Luis Rueda García, et al.
Publicado: (2026)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
por: Zhidong Zhou, et al.
Publicado: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
por: Virginia Solitano, et al.
Publicado: (2024)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
por: Silvio Danese, et al.
Publicado: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
por: Jeffrey D. McCurdy, et al.
Publicado: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
por: José Luis Rueda García, et al.
Publicado: (2026)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
por: Ziheng Calvin Xu, et al.
Publicado: (2025)

Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
por: María José Casanova, et al.
Publicado: (2025)

Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis
por: Wei‐Zhen Tang, et al.
Publicado: (2024)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
por: Maryam Irshad, et al.
Publicado: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
por: Rónán O'Connor, et al.
Publicado: (2026)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
por: Maryam Alahmad, et al.
Publicado: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
por: You‐Jian Xu, et al.
Publicado: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
por: Manjeet Kumar Goyal, et al.
Publicado: (2026)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
por: Jia‐Yong Su, et al.
Publicado: (2025)

Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study
por: Clara Yzet, et al.
Publicado: (2025)

Research Communication: Sexual Dysfunction is a Common Early Challenge in Newly Diagnosed Inflammatory Bowel Disease
por: Mohamed Attauabi, et al.
Publicado: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
por: Isabella Lurje, et al.
Publicado: (2025)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
por: Shlomi Cohen, et al.
Publicado: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
por: Shupeng Zhao, et al.
Publicado: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
por: Kuo‐Cheng Wu, et al.
Publicado: (2024)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
por: Emmanuel Pio Pastore
Publicado: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
por: Xinglin Li, et al.
Publicado: (2026)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
por: Antoine Meyer, et al.
Publicado: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
por: Leyu Zhou, et al.
Publicado: (2024)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
por: D. Bogatic, et al.
Publicado: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
por: Weilun Gao, et al.
Publicado: (2024)

Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
por: Moeko Komatsu, et al.
Publicado: (2024)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
por: Nicolas Richard, et al.
Publicado: (2026)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
por: Abhirup Chatterjee, et al.
Publicado: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
por: Chang Liu, et al.
Publicado: (2026)